Compare AMWL & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWL | CBUS |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Agricultural Chemicals |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.4M | 69.9M |
| IPO Year | 2020 | 2017 |
| Metric | AMWL | CBUS |
|---|---|---|
| Price | $4.86 | $1.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $7.58 | ★ $20.00 |
| AVG Volume (30 Days) | 139.1K | ★ 188.7K |
| Earning Date | 02-11-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $265,023,000.00 | $3,794,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $109.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $3.71 | $1.09 |
| 52 Week High | $12.95 | $3.40 |
| Indicator | AMWL | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 61.85 | 64.89 |
| Support Level | $4.48 | $1.59 |
| Resistance Level | $4.67 | $1.80 |
| Average True Range (ATR) | 0.21 | 0.14 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 82.46 | 89.70 |
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.